Twist Bioscience Corporation reported record revenue of USD 103.7 million for the first quarter (Q1) of fiscal year 2026, representing a 17% increase. Gross margin for Q1 FY2026 reached 52.0%, an improvement of approximately 4 points. The company raised its full-year revenue guidance to a range of USD 435 million to USD 440 million, indicating anticipated growth of 16% at the midpoint. For the second quarter (Q2) of FY2026, Twist expects revenue of approximately USD 107 million to USD 108 million. The company reiterated its expectation to achieve adjusted EBITDA breakeven in the fourth quarter (Q4) of FY2026. During Q1 FY2026, Twist shipped products to approximately 2,538 customers and physically shipped about 271,000 genes, with an additional 50,000-plus genes manufactured for data characterization. The company also launched research-grade Plasmid DNA Preps designed to support pre-clinical studies for pharmaceutical and biotech customers. Twist stated it remains focused on consistent revenue growth, maintaining gross margins above 50%, and disciplined investment for scalable and sustainable growth opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Twist Bioscience Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001581280-26-000016), on February 02, 2026, and is solely responsible for the information contained therein.